Pfizer’s Talzenna cleared for breast cancer
US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Read More
Tag: gBRCAm
Speedy review for AZ’ Lynparza in breast cancer
AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
